These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17320237)

  • 21. Point: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes.
    Kahn SE; Zinman B
    Diabetes Care; 2007 Jun; 30(6):1672-6. PubMed ID: 17351271
    [No Abstract]   [Full Text] [Related]  

  • 22. Thiazolidinediones.
    Edelman SV
    N Engl J Med; 2005 Jan; 352(2):205-7; author reply 205-7. PubMed ID: 15651124
    [No Abstract]   [Full Text] [Related]  

  • 23. [Glitazones--again].
    Halse J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2707; author reply 2707. PubMed ID: 17952161
    [No Abstract]   [Full Text] [Related]  

  • 24. [The true place of glitazones in the treatment of diabetes: after the PROactive study].
    Lindberg M; Jørgensen PH; Kampmann JP
    Ugeskr Laeger; 2006 Jun; 168(25):2477-9; author reply 2479-80. PubMed ID: 16824389
    [No Abstract]   [Full Text] [Related]  

  • 25. The pluses of pioglitazone.
    Meyers L
    Diabetes Forecast; 2005 Sep; 58(9):39. PubMed ID: 16187433
    [No Abstract]   [Full Text] [Related]  

  • 26. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 27. [Glitazones in type 2 diabetes--documented risks, uncertain benefits].
    Håkansson J
    Lakartidningen; 2007 Oct 24-30; 104(43):3198-200. PubMed ID: 18018937
    [No Abstract]   [Full Text] [Related]  

  • 28. The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.
    Itakura H; Abbasi F; Lamendola C; Basina M; Reaven G
    Diabetes Obes Metab; 2008 Aug; 10(8):685-7. PubMed ID: 18476981
    [No Abstract]   [Full Text] [Related]  

  • 29. The rosiglitazone controversy: the Indian perspective.
    Mohan V; Joshi SR
    J Assoc Physicians India; 2007 Jul; 55():477-80. PubMed ID: 17907495
    [No Abstract]   [Full Text] [Related]  

  • 30. Which should we ADOPT: sulphonylureas or glitazones?
    Koshiyama H; Inagaki N; Seino Y
    Diabet Med; 2007 Jul; 24(7):804. PubMed ID: 17596243
    [No Abstract]   [Full Text] [Related]  

  • 31. Introduction: beyond glycemic control in type 2 diabetes.
    Barnett AH
    Curr Med Res Opin; 2006; 22 Suppl 2():S1-4. PubMed ID: 16914070
    [No Abstract]   [Full Text] [Related]  

  • 32. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of the DREAM Study.
    Davidson MB
    Diabetes Care; 2007 Feb; 30(2):418-20. PubMed ID: 17259522
    [No Abstract]   [Full Text] [Related]  

  • 34. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 35. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
    Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
    Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P
    Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 38. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
    Misbin RI
    Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
    [No Abstract]   [Full Text] [Related]  

  • 39. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus.
    Koski RR
    Diabetes Educ; 2006; 32(6):869-76. PubMed ID: 17102154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.